Compass Therapeutics, Inc. 8-K

What Happened Compass Therapeutics, Inc. announced on June 22, 2026 that its Board of Directors approved and adopted Second Amended and Restated Bylaws, effective June 22, 2026. The New Bylaws amend and restate the company’s prior Amended and Restated Bylaws (dated July 17, 2020) and include a provision designating exclusive jurisdiction for actions asserting claims under the Securities Act of 1933.

Key Details

• Board approved adoption date: June 22, 2026.
• Document: Second Amended and Restated Bylaws (filed as Exhibit 3.1 to the 8-K).
• Venue provision: exclusive federal court jurisdiction for Securities Act claims in the U.S. District Court for the District of Delaware and the U.S. District Court for the District of Massachusetts.
• The New Bylaws amend and replace the company’s Existing Bylaws dated July 17, 2020.

Why It Matters For investors, this change clarifies and limits where Securities Act claims against Compass Therapeutics can be brought, potentially centralizing and standardizing litigation forum and procedure. The filing itself is procedural (an amendment to corporate governance documents) rather than a financial disclosure, but it is relevant to shareholders because bylaws govern corporate processes and can affect litigation strategy and related costs. The full text of the New Bylaws is available as Exhibit 3.1 to the 8‑K for anyone wanting the exact language.